Nevakar Inc.
Repositioning Drugs for a Better Outcome®
Bridgewater, United States
35 employees
Private Equity
Total: $135.00M
Biopharma, Biotechnology +1
General Information
Get notified when Nevakar Inc. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Nevakar Inc.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biopharma
About Nevakar Inc.
Taxonomy: specialty pharmaceuticals, injectable medications, ophthalmic products, innovative drug development, FDA-approved molecules, R&D, clinical research, unmet medical needs, pharmaceutical company, NJ Center of Excellence, management team, drug repositioning, enhanced products, commercial needs, state-of-the-art infrastructure
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Private Equity Round | •••••• | 1 |
|
18 Jun 2019 |
| Debt Financing | •••••• | 2 |
|
30 Nov 2018 |
| Private Equity Round | •••••• | - | 28 Jul 2016 |
Nevakar Inc. Alternatives & Competitors
Developing specialized cancer, CNS and infectious disease pharmaceutical products
We're developing breakthrough technology for oral delivery of biologics
Pyramid Labs
Delpharm
FAQ About Nevakar Inc.
Don't just browse. Track.
Signal Tracker monitors Nevakar Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
